Editas Book Value Per Share from 2010 to 2024

EDIT Stock

USD 2.37 0.04 1.66%

Editas Medicine Book Value Per Share yearly trend continues to be comparatively stable with very little volatility. Book Value Per Share will likely drop to 2.56 in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Editas Medicine according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

4.59545963

Current Value

2.56

Quarterly Volatility

5.21869033

Credit Downgrade

Yuan Drop

Covid

Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 3 M or Selling General Administrative of 57.9 M, as well as many indicators such as Price To Sales Ratio of 9.36, Dividend Yield of 0.0 or PTB Ratio of 2.31. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.

Check out the analysis of Editas Medicine Correlation against competitors.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Latest Editas Medicine's Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Editas Medicine over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Editas Medicine's Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 2.13 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Editas Book Value Per Share Regression Statistics

	Arithmetic Mean	1.34
	Geometric Mean	4.45
	Coefficient Of Variation	388.94
	Mean Deviation	4.65
	Median	4.18
	Standard Deviation	5.22
	Sample Variance	27.23
	Range	14.0549
	R-Value	0.83
	Mean Square Error	8.90
	R-Squared	0.70
	Significance	0.0001
	Slope	0.97
	Total Sum of Squares	381.29

Editas Book Value Per Share History

	2024	2.56
	2023	4.6
	2021	8.19
	2020	6.72
	2019	5.25
	2018	5.01
	2017	5.16

Other Fundumenentals of Editas Medicine

Tangible Book Value Per Share

Editas Medicine Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Current Deferred Revenue	Long Term Debt	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Short Term Debt	Common Stock	Short Term Investments	Capital Surpluse	Long Term Debt Total	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock
Total Assets		0.95	-0.81	-0.83	0.86	0.75	0.99	0.61	0.95	0.66	0.85	0.38	0.93	0.75	0.85	0.8	0.96	0.92	-0.66	0.78	0.6	0.75	0.65
Total Stockholder Equity	0.95		-0.81	-0.83	0.82	0.51	0.91	0.5	1.0	0.59	0.68	0.39	0.86	0.58	0.82	0.84	0.93	0.93	-0.63	0.87	0.62	0.83	0.72
Net Debt	-0.81	-0.81		0.57	-0.7	-0.52	-0.84	-0.81	-0.8	-0.87	-0.66	-0.09	-0.73	-0.58	-0.52	-0.49	-0.76	-0.68	0.45	-0.53	-0.63	-0.41	-0.34
Retained Earnings	-0.83	-0.83	0.57		-0.87	-0.54	-0.77	-0.36	-0.85	-0.41	-0.67	-0.78	-0.88	-0.6	-0.89	-0.93	-0.8	-0.94	0.9	-0.77	-0.21	-0.85	-0.92
Accounts Payable	0.86	0.82	-0.7	-0.87		0.64	0.82	0.57	0.85	0.61	0.78	0.55	0.86	0.7	0.87	0.82	0.79	0.91	-0.68	0.59	0.23	0.7	0.71
Total Liab	0.75	0.51	-0.52	-0.54	0.64		0.81	0.63	0.52	0.57	0.89	0.24	0.77	0.87	0.61	0.41	0.67	0.55	-0.49	0.31	0.34	0.3	0.27
Total Current Assets	0.99	0.91	-0.84	-0.77	0.82	0.81		0.69	0.9	0.71	0.86	0.29	0.94	0.78	0.78	0.7	0.95	0.85	-0.63	0.7	0.63	0.63	0.54
Property Plant Equipment	0.61	0.5	-0.81	-0.36	0.57	0.63	0.69		0.5	0.86	0.72	-0.02	0.66	0.69	0.38	0.18	0.56	0.41	-0.38	0.09	0.27	0.02	0.05
Net Tangible Assets	0.95	1.0	-0.8	-0.85	0.85	0.52	0.9	0.5		0.59	0.7	0.44	0.87	0.6	0.85	0.87	0.93	0.96	-0.67	0.86	0.57	0.84	0.76
Current Deferred Revenue	0.66	0.59	-0.87	-0.41	0.61	0.57	0.71	0.86	0.59		0.68	0.11	0.62	0.66	0.39	0.26	0.58	0.47	-0.38	0.28	0.4	0.23	0.12
Long Term Debt	0.85	0.68	-0.66	-0.67	0.78	0.89	0.86	0.72	0.7	0.68		0.31	0.82	0.98	0.82	0.57	0.71	0.71	-0.54	0.47	0.31	0.49	0.47
Net Receivables	0.38	0.39	-0.09	-0.78	0.55	0.24	0.29	-0.02	0.44	0.11	0.31		0.54	0.29	0.57	0.69	0.38	0.59	-0.84	0.45	-0.3	0.68	0.8
Deferred Long Term Liab	0.93	0.86	-0.73	-0.88	0.86	0.77	0.94	0.66	0.87	0.62	0.82	0.54		0.73	0.81	0.76	0.94	0.87	-0.83	0.65	0.36	0.66	0.66
Short Long Term Debt	0.75	0.58	-0.58	-0.6	0.7	0.87	0.78	0.69	0.6	0.66	0.98	0.29	0.73		0.77	0.48	0.59	0.61	-0.49	0.4	0.24	0.41	0.41
Short Term Debt	0.85	0.82	-0.52	-0.89	0.87	0.61	0.78	0.38	0.85	0.39	0.82	0.57	0.81	0.77		0.9	0.74	0.92	-0.68	0.75	0.25	0.82	0.85
Common Stock	0.8	0.84	-0.49	-0.93	0.82	0.41	0.7	0.18	0.87	0.26	0.57	0.69	0.76	0.48	0.9		0.76	0.96	-0.75	0.83	0.3	0.92	0.95
Short Term Investments	0.96	0.93	-0.76	-0.8	0.79	0.67	0.95	0.56	0.93	0.58	0.71	0.38	0.94	0.59	0.74	0.76		0.87	-0.7	0.76	0.6	0.71	0.61
Capital Surpluse	0.92	0.93	-0.68	-0.94	0.91	0.55	0.85	0.41	0.96	0.47	0.71	0.59	0.87	0.61	0.92	0.96	0.87		-0.73	0.81	0.4	0.87	0.87
Long Term Debt Total	-0.66	-0.63	0.45	0.9	-0.68	-0.49	-0.63	-0.38	-0.67	-0.38	-0.54	-0.84	-0.83	-0.49	-0.68	-0.75	-0.7	-0.73		-0.59	-0.06	-0.66	-0.78
Net Invested Capital	0.78	0.87	-0.53	-0.77	0.59	0.31	0.7	0.09	0.86	0.28	0.47	0.45	0.65	0.4	0.75	0.83	0.76	0.81	-0.59		0.61	0.93	0.8
Net Working Capital	0.6	0.62	-0.63	-0.21	0.23	0.34	0.63	0.27	0.57	0.4	0.31	-0.3	0.36	0.24	0.25	0.3	0.6	0.4	-0.06	0.61		0.34	0.1
Long Term Investments	0.75	0.83	-0.41	-0.85	0.7	0.3	0.63	0.02	0.84	0.23	0.49	0.68	0.66	0.41	0.82	0.92	0.71	0.87	-0.66	0.93	0.34		0.91
Capital Stock	0.65	0.72	-0.34	-0.92	0.71	0.27	0.54	0.05	0.76	0.12	0.47	0.8	0.66	0.41	0.85	0.95	0.61	0.87	-0.78	0.8	0.1	0.91

Click cells to compare fundamentals

About Editas Medicine Financial Statements

Editas Medicine shareholders use historical fundamental indicators, such as Book Value Per Share, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Book Value Per Share	4.60	2.56
Tangible Book Value Per Share	4.60	2.56

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC